Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
Shanghai Chest Hospital · Chinese Academy of Medical Sciences & Peking Union Medical College · +36 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
7
total citations
- FWCI
- 131.33
- Percentile
- 100%
- References
- 32
Too recent for citation history.
Authors
113- SLShun LuCorresponding
Shanghai Chest Hospital
- JWJie Wang
Chinese Academy of Medical Sciences & Peking Union Medical College
- NYNong Yang
Central South University, Hunan Cancer Hospital
- DLDongqing Lv
Wenzhou Medical University, Zhejiang Taizhou Hospital, Taizhou University
- LCLijuan Chen
Zhengzhou University, Henan Cancer Hospital
Topics & keywords
Topics
Keywords
- Osimertinib
- Interim analysis
- Lung cancer
- Chemotherapy
- Randomized controlled trial
- Interim
- Exploratory analysis
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.